eli lilly phase 3 trial retatrutide #elililly #retatrutide #weightloss #obesitycare #glp1 #healthcareinnovation #pharma #biopharma #metabolichealth #pharmanews Lilly announces more next-gen obesity

The same patient on retatrutide lands at roughly 179 lbs a BMI trajectory that changes downstream health outcomes, surgical candidacy, and cardiovascular risk in meaningfully different ways

[1] When considering GLP-1 side effects, it is best to consult your doctor about the individual GLP-1 medication they prescribed

Disclaimer : The information provided here is for general knowledge only and should not be considered medical advice

Stay up to date with recent developments, meet colleagues and be part of the key discussions that will shape the future of diabetes research and care

The label claims 99 percent purity but what does that actually mean in this context

A review of the pharmacotherapy of obesity: GLP-1 receptor agonists